^
    16h
    BGB-A317-290-LTE1: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (clinicaltrials.gov)
    P3, N=404, Active, not recruiting, BeOne Medicines | Enrolling by invitation --> Active, not recruiting
    Enrollment closed
    |
    temozolomide • Lenvima (lenvatinib) • Tevimbra (tislelizumab-jsgr) • Fruzaqla (fruquintinib) • Partruvix (pamiparib) • Ziihera (zanidatamab-hrii) • Avzivi (bevacizumab-tnjn) • ociperlimab (BGB-A1217) • sitravatinib (MGCD516) • BGB-15025 • BGB-A445 • alcestobart (LBL-007) • surzebiclimab (BGB-A425)
    12d
    BGB-A317-290-LTE1: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (clinicaltrials.gov)
    P3, N=430, Enrolling by invitation, BeOne Medicines | Trial completion date: Dec 2026 --> Jul 2026 | Trial primary completion date: Dec 2026 --> Jul 2026
    Trial completion date • Trial primary completion date
    |
    temozolomide • Lenvima (lenvatinib) • Tevimbra (tislelizumab-jsgr) • Fruzaqla (fruquintinib) • Partruvix (pamiparib) • Ziihera (zanidatamab-hrii) • Avzivi (bevacizumab-tnjn) • ociperlimab (BGB-A1217) • sitravatinib (MGCD516) • BGB-15025 • BGB-A445 • alcestobart (LBL-007) • surzebiclimab (BGB-A425)
    17d
    Denosumab Combined With PARP Inhibitors and Chemoradiotherapy for Treating Triple Negative Breast Cancer With Bone Metastasis: A Case Report. (PubMed, Cancer Rep (Hoboken))
    This case suggests that the combination of denosumab with PARP inhibitors and chemoradiotherapy may provide a potential therapeutic strategy for TNBC patients with bone metastasis. Further studies are warranted to validate the efficacy and safety of this combined treatment approach.
    Journal
    |
    HRD (Homologous Recombination Deficiency)
    |
    HRD
    |
    capecitabine • Partruvix (pamiparib) • Prolia (denosumab)
    18d
    Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer (clinicaltrials.gov)
    P1/2, N=29, Completed, Sun Yat-sen University | Recruiting --> Completed | Trial completion date: Aug 2025 --> Jan 2026
    Trial completion • Trial completion date • Platinum resistant
    |
    Partruvix (pamiparib) • Sulanda (surufatinib)
    24d
    Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer (clinicaltrials.gov)
    P1, N=30, Recruiting, University of Chicago | Trial completion date: Jan 2026 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    Tevimbra (tislelizumab-jsgr) • Partruvix (pamiparib) • hydroxyurea • fluorouracil topical
    3ms
    BGB-290-302: Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer (clinicaltrials.gov)
    P3, N=224, Active, not recruiting, BeiGene | Trial completion date: Jun 2027 --> Jan 2027 | Trial primary completion date: Jun 2026 --> Dec 2025
    Trial completion date • Trial primary completion date • Platinum sensitive
    |
    Partruvix (pamiparib)
    3ms
    Efficacy and safety of PARP inhibitors in metastatic breast cancer patients with homologous recombination repair pathway gene mutations: a retrospective multicenter real-world study. (PubMed, Ther Adv Med Oncol)
    In total, 62 MBC patients treated with olaparib (N = 55), talazoparib (N = 4), pamiparib (N = 2), and fluzoparib (N = 1) were enrolled. Hematologic toxicity was the most common grade ⩾3 AEs. PARPis showed promising PFS and tolerable toxicity in the real-world treatment of Chinese MBC patients with HRR-related gene mutations.
    Retrospective data • Journal • Real-world evidence • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency)
    |
    Lynparza (olaparib) • Talzenna (talazoparib) • Partruvix (pamiparib) • AiRuiYi (fluzoparib)
    3ms
    Neoadjuvant pamiparib plus abiraterone and androgen deprivation therapy for high-risk/very high-risk localized prostate cancer: an open-label, single-arm, phase 2 study. (PubMed, Prostate Cancer Prostatic Dis)
    Neoadjuvant pamiparib plus abiraterone and ADT demonstrated efficacy, safety, and potential QoL benefits in HRPCa/VHRPCa.
    P2 data • Journal • PARP Biomarker
    |
    HRD (Homologous Recombination Deficiency)
    |
    abiraterone acetate • Partruvix (pamiparib)
    3ms
    PNOC017: BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas (clinicaltrials.gov)
    P1, N=78, Active, not recruiting, University of California, San Francisco | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    IDH2 mutation
    |
    temozolomide • Partruvix (pamiparib)
    4ms
    Drug combination discovery assisted by AI and untargeted metabolomics: pamiparib and anlotinib synergistic potentiation for ovarian cancer treatment. (PubMed, Front Pharmacol)
    In vivo, significant downregulation of p-PI3K, p-Akt, Bcl-2, and HIF1-α, and upregulation of BAX protein expression confirmed that the mechanism of action of combination therapy is related to PI3K/Akt pathway. The combination of PAM and ANL was more effective than monotherapy for treating ovarian cancer and holds potential to become a new therapeutic approach for ovarian cancer.
    Journal • PARP Biomarker • IO biomarker • Metabolomic study
    |
    BCL2 (B-cell CLL/lymphoma 2) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • BAX (BCL2-associated X protein) • ANXA5 (Annexin A5)
    |
    Focus V (anlotinib) • Partruvix (pamiparib)
    4ms
    Poly (ADP-ribose) polymerase (PARP) inhibitors approved for the treatment of cancer. (PubMed, Pharmacol Res)
    The FDA has approved four PARP inhibitors (olaparib, rucaparib, niraparib, and talazoparib) for the treatment of ovarian, breast, prostate, and pancreatic cancer...The Chinese NMPA has approved three PARP antagonists (fuzuloparib, pamiparib, senaparib) for the treatment of ovarian cancer. All seven of these drugs are orally bioavailable and fall within the criteria of Lipinski's rule of five. Drug resistance develops in most PARP-inhibitor-treated cancer patients within one or two years.
    Review • Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency)
    |
    Lynparza (olaparib) • Talzenna (talazoparib) • Zejula (niraparib) • Rubraca (rucaparib) • Partruvix (pamiparib) • AiRuiYi (fluzoparib) • Paishuning (senaparib)
    5ms
    A prospective, randomized, open-label, controlled clinical study comparing ivosimod combined with chemotherapy versus pamiparib combined with chemotherapy as neoadjuvant therapy for NSCLC (ChiCTR2500108304)
    P2, N=168, Recruiting, Peking University People's Hospital; Peking University People's Hospital
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Partruvix (pamiparib) • Anniko (penpulimab-kcqx) • Yidafan (ivonescimab)